There are 133 papers on hyperkalemia in aging research: 21 trials and 35 observational studies in people, 1 in animals, 65 reviews.
58 new papers in 30 daysSee all 152 papers on hyperkalemia
At a glance
Hyperkalemia is linked with in-hospital mortality in people with acute decompensated heart failure and cardiovascular mortality in people receiving maintenance hemodialysis. Human trials report increased hyperkalemia with finerenone and potassium-enriched salt substitutes; a trial reports less spironolactone-associated hyperkalemia with added dapagliflozin on background irbesartan therapy.
45 findings in 41 papers from 2016 to 2026, 27 of them since May 2026
“salt substitute increased mean serum potassium and led to more frequent biochemical hyperkalemia”
- Human trial21
- Humans35
- Animals1
- In silico2
Interventions
11Finerenone
upin humans2RR 2.03
2 studies
Finerenone
upin humans2RR 2.03
Finerenone increases hyperkalemia in humans (RR 2.03, 95% CI 1.82–2.26).
“Finerenone increased hyperkalaemia (RR 2.03, 95% CI: 1.82-2.26)”
Human trial
Diabetes, obesity & metabolism
Finerenone increases hyperkalemia in humans (Chronic kidney disease with type 2 diabetes).
“Finerenone increased hyperkalemia without increasing acute kidney injury.”
ReviewChronic kidney disease with type 2 diabetes
Diabetes, obesity & metabolism
Dietary potassium intake
no changein humans1
1 study
Dietary potassium intake
no changein humans1
Dietary potassium intake was not clearly linked with hyperkalemia in humans (maintenance hemodialysis patients).
“Dietary potassium intake was not associated with serum potassium levels or hyperkalaemia risk”
Humansmaintenance hemodialysis patients
The British journal of nutrition
Baxdrostat
upin humans1
1 study
Baxdrostat
upin humans1
Baxdrostat increases hyperkalemia in humans (resistant or uncontrolled hypertension; compared with placebo) (2.6% with baxdrostat versus 0.4% with placebo).
“Hyperkalemia (serum K + >6.0 mmol/L) occurred in 2.6% of baxdrostat-treated patients versus 0.4% with placebo.”
Reviewresistant or uncontrolled hypertension; compared with placebo
Nocturnal Blood Pressure Reduction with Baxdrostat: A Targeted Literature Review and Meta-Analysis
AHA Scientific Sessions 2026 abstract
Potassium-enriched salt substitutes
upin humans1RR 2.1
1 study
Potassium-enriched salt substitutes
upin humans1RR 2.1
Potassium-enriched salt substitutes increase hyperkalemia in humans (RR 2.10 (95% CI 1.35-3.26)).
“whilst biochemical hyperkalaemia events increased significantly (RR 2.10; 95% CI 1.35-3.26; I2=0%)”
Human trial75% NaCl / 25% KCl formulationn = 24,998
ESC Congress 2026 abstract
Eplerenone
no changein humans1
1 study
Eplerenone
no changein humans1
Eplerenone showed no clear effect on hyperkalemia in humans (Obesity and essential hypertension; compared with irbesartan-based treatment) (1.2% versus 1.3% (p=1.00)).
“Hyperkalemia (≥5.5 mmol/L) was rare and occurred in 1.2% and 1.3% of patients, respectively (p=1.00), with no treatment discontinuations.”
Human trialObesity and essential hypertension; compared with irbesartan-based treatment25 mg twice daily6 monthsn = 162
ESC Congress 2026 abstract
Amiloride
upin mice1
1 study
Amiloride
upin mice1
Amiloride increases hyperkalemia in KLhet mice.
“Pharmacological ENaC inhibition with amiloride precipitated severe hyperkalemia in KLhet mice.”
Animalsin KLhet mice
Klotho deficiency disrupts potassium balance in mice
Acta physiologica (Oxford, England)
Rapamycin
downin mice1
1 study
Rapamycin
downin mice1
Rapamycin decreases hyperkalemia in KLhet mice.
“treatment with the mTORC1 inhibitor rapamycin or Klotho supplementation suppressed renal mTORC1 signaling, restored plasma membrane ROMK1 abundance, increased urinary potassium excretion, and normalized serum potassium levels”
Animalsin KLhet micekidney
Klotho deficiency disrupts potassium balance in mice
Acta physiologica (Oxford, England)
Finerenone + SGLT2 inhibitors
upin humans1RR 2.48
1 study
Finerenone + SGLT2 inhibitors
upin humans1RR 2.48
Finerenone + SGLT2 inhibitors increase hyperkalemia in humans (finerenone combined with empagliflozin, compared with empagliflozin alone) (RR 2.48, 95% CI 1.22–5.06).
“Finerenone plus empagliflozin was associated with a higher risk of hyperkalaemia than empagliflozin alone (RR 2.48, 95% CI: 1.22-5.06)”
Human trialfinerenone combined with empagliflozin, compared with empagliflozin alone
Diabetes, obesity & metabolism
SGLT2 inhibitors
no changein humans1
1 study
SGLT2 inhibitors
no changein humans1
SGLT2 inhibitors were not clearly linked with hyperkalemia in humans.
“Hyperkalemia was associated with lower eGFR, but not with SGLT2i treatment”
Humans
Frontiers in transplantation
Dapagliflozin + spironolactone
downin humans1
1 study
Dapagliflozin + spironolactone
downin humans1
Dapagliflozin + spironolactone decreases hyperkalemia in humans (on irbesartan background therapy; relative to spironolactone-associated hyperkalemia).
“while attenuating the risk of spironolactone-associated hyperkalemia”
Human trialon irbesartan background therapy; relative to spironolactone-associated hyperkalemia72 weeks
The American journal of the medical sciences
All 11Fewer
Upstream
1Klotho
downin mice1
1 study
Klotho
downin mice1
Klotho decreases hyperkalemia in KLhet mice.
“treatment with the mTORC1 inhibitor rapamycin or Klotho supplementation suppressed renal mTORC1 signaling, restored plasma membrane ROMK1 abundance, increased urinary potassium excretion, and normalized serum potassium levels”
Animalsin KLhet micesupplementationkidney
Klotho deficiency disrupts potassium balance in mice
Acta physiologica (Oxford, England)
Associations
18Baxdrostat
upin humans8downin humans1OR 5.14–5.98
9 studies
Baxdrostat
upin humans8downin humans1OR 5.14–5.98
Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension).
“A confirmed potassium level of more than 6 mmol/L occurred in three (3%) of the 108 baxdrostat recipients and in none of the placebo recipients.”
Human trialresistant hypertension2 mg orally once daily12 weeksn = 217
Lancet (London, England)
Baxdrostat raises the risk of hyperkalemia in humans (hypertension; compared with placebo) (8.9% vs. 1.2%; OR 5.98).
“Safety analysis showed higher odds of hyperkalemia (8.9% vs. 1.2%; OR 5.98; P = 0.008)”
Reviewhypertension; compared with placebo
AHA Scientific Sessions 2026 abstract
Baxdrostat raises the risk of hyperkalemia in humans (hypertension; potassium ≥6.0 mmol/L) (OR 5.14 (95% CI 1.76–14.97)).
“The pooled odds ratio for potassium ≥6.0 mmol/L was 5.14 (95% CI: 1.76 to 14.97).”
Reviewhypertension; potassium ≥6.0 mmol/L
AHA Scientific Sessions 2026 abstract
Baxdrostat raises the risk of hyperkalemia in humans (resistant or uncontrolled hypertension; compared with placebo) (RR 4.39; 95% CI 2.05–9.40).
“Baxdrostat increased hyperkalemia (RR 4.39; 95% CI 2.05-9.40; p=0.002)”
Reviewresistant or uncontrolled hypertension; compared with placebo
AHA Scientific Sessions 2026 abstract
Baxdrostat lowers the risk of hyperkalemia in humans (resistant hypertension; compared with spironolactone) (Hyperkalemia (>6.0 mEq/L): baxdrostat 2 mg 3.0%, spironolactone 9.6% (95% CI 1.6-40.6)).
“demonstrates comparable blood pressure reduction to spironolactone in resistant hypertension but with a significantly lower risk of hyperkalemia.”
Reviewresistant hypertension; compared with spironolactone
AHA Scientific Sessions 2026 abstract
Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension; compared with placebo) (RR 3.77 (95% CI 2.29–6.21); 103 events with baxdrostat versus 19 with placebo).
“Hyperkalemia risk was increased (risk ratio [RR] 3.77 ; 95% CI 2.29-6.21;”
Reviewresistant hypertension; compared with placebon = 1,996
AHA Scientific Sessions 2026 abstract
Baxdrostat raises the risk of hyperkalemia in humans (uncontrolled and resistant hypertension; compared with placebo) (RR 5.35; 95% CI 1.76, 16.25; NNH 19).
“There was, however, a significant increase in the incidence of hyperkalemia (RR 5.35; 95% CI 1.76, 16.25; NNH 19; I2 = 0)”
Reviewuncontrolled and resistant hypertension; compared with placebon = 1,729
ESC Congress 2026 abstract
Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension) (RR 2.87, 95% CI 1.61-5.11).
“baxdrostat increased hyperkalemia risk (serum potassium ≥5.5 mmol/L) (RR: 2.87; 95% CI: 1.61-5.11; moderate certainty)”
Reviewresistant hypertension
Cureus
Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension).
“Baxdrostat and Lorundrostat were associated with significant increases in serum potassium levels and hyperkalemia.”
Reviewresistant hypertension
Journal of hypertension
Aldosterone synthase inhibitors
upin humans4RR 4.43–8.97
4 studies
Aldosterone synthase inhibitors
upin humans4RR 4.43–8.97
Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (uncontrolled or resistant hypertension; compared with placebo) (RR 8.97).
“Regarding safety, ASIs significantly increased hyperkalemia (RR 8.97)”
Reviewuncontrolled or resistant hypertension; compared with placebo
AHA Scientific Sessions 2026 abstract
Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (uncontrolled or resistant hypertension; compared with placebo) (OR 4.93, 95% CI 1.99–12.20).
“ASIs significantly increased hyperkalemia, hypotension, and treatment discontinuation without increasing serious adverse events.”
Reviewuncontrolled or resistant hypertension; compared with placebo
AHA Scientific Sessions 2026 abstract
Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (hypertension) (RR 4.43, 95% CI 2.40–8.19).
“Hyperkalemia was more common with treatment (RR 4.43, 95% CI 2.40-8.19)”
Reviewhypertension
AHA Scientific Sessions 2026 abstract
Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (RR 5.04).
“Safety signals included reduced eGFR (MD -6.91 mL/min/1.73 m2), hyperkalemia [risk ratio (RR) 5.04], hyponatremia (RR 2.11), and symptomatic hypotension (RR 3.17)”
Review
Cardiology in review
Finerenone
upin humans3downin humans1HR 1.35–1.47
4 studies
Finerenone
upin humans3downin humans1HR 1.35–1.47
Finerenone raises the risk of hyperkalemia in humans (CKD and T2D; irrespective of initiation strategy).
“Rates of hyperkalemia were higher with finerenone”
Human trialCKD and T2D; irrespective of initiation strategy180 days
ESC Congress 2026 abstract
Finerenone is associated with hyperkalemia in humans (Patients with chronic kidney disease and type 2 diabetes; compared with nonusers) (HR 1.47, 95% CI 1.31–1.65).
“Finerenone initiators were more likely to experience hyperkalemia (HR, 1.47; 95% CI, 1.31-1.65).”
HumansPatients with chronic kidney disease and type 2 diabetes; compared with nonusersmale, 53%s
ESC Congress 2026 abstract
Finerenone is linked with a lower risk of hyperkalemia in humans (CKD and non-DM patients versus steroidal MRAs).
“a significantly reduced risk of hyperkalemia in CKD and non-DM patients”
HumansCKD and non-DM patients versus steroidal MRAs
Current problems in cardiology
Finerenone is associated with hyperkalemia in humans (HR 1.35; 95% CI 1.11–1.69; risk-based analyses were not statistically significant).
“Hyperkalemia occurred more often with finerenone (HR 1.35; 95% CI: 1.11 to 1.69) although risk-based analyses did not reach statistical significance.”
HumansChronic kidney disease and type 2 diabetes; finerenone added to SGLT2 inhibitor therapy versus SGLT2 inhibitor monotherapy1 year
The American journal of cardiology
Cardiovascular mortality
upin humans1
1 study
Cardiovascular mortality
upin humans1
Hyperkalemia predicts cardiovascular mortality in humans (maintenance hemodialysis patients; serum potassium ≥6.0 mmol/L) (aHR 1.59, 95% CI 1.06–2.38).
“severe hyperkalaemia (serum potassium ≥6·0 mmol/L) independently predicted cardiovascular mortality (aHR: 1·59, 95% CI: 1·06–2·38)”
Humansmaintenance hemodialysis patients; serum potassium ≥6.0 mmol/L
The British journal of nutrition
Hepatic angiotensinogen-lowering RNA therapeutics
upin humans1RR 2.8
1 study
Hepatic angiotensinogen-lowering RNA therapeutics
upin humans1RR 2.8
Hepatic angiotensinogen-lowering RNA therapeutics raise the risk of hyperkalemia in humans (hypertension; versus control) (RR 2.80; 95% CI 1.30 to 6.04).
“Hyperkalemia was more frequent with RNA therapeutics (RR 2.80; 95% CI 1.30 to 6.04)”
Reviewhypertension; versus control
AHA Scientific Sessions 2026 abstract
Finerenone + SGLT2 inhibitors
upin humans1OR 1.6
1 study
Finerenone + SGLT2 inhibitors
upin humans1OR 1.6
Finerenone + SGLT2 inhibitors raise the risk of hyperkalemia in humans (Chronic kidney disease; compared with SGLT2 inhibitor monotherapy) (OR 1.60, 95% CI 1.06–2.42).
“combination therapy was associated with a higher risk of hyperkalemia (OR: 1.60; 95% CI: 1.06-2.42; p = 0.02; I 2 = 49%)”
ReviewChronic kidney disease; compared with SGLT2 inhibitor monotherapyMedian follow-up: 12.5 monthsn = 8,196
AHA Scientific Sessions 2026 abstract
Lorundrostat
upin humans1OR 7.64
1 study
Lorundrostat
upin humans1OR 7.64
Lorundrostat raises the risk of hyperkalemia in humans (Hypertension; compared with placebo) (OR 7.64 [1.40-41.78]).
“Significant hyperkalemia was observed with lorundrostat 100mg (OR 7.64 [1.40-41.78])”
ReviewHypertension; compared with placebo100 mg
AHA Scientific Sessions 2026 abstract
In-hospital mortality
upin humans1OR 2.63
1 study
In-hospital mortality
upin humans1OR 2.63
Hyperkalemia is associated with in-hospital mortality in humans (acute decompensated heart failure; K+ >5.5 mmol/L) (OR 2.63).
“Independent risk factors were diabetes (OR 1.81), NYHA III–IV (OR 1.97), MLHFQ ≥41 (OR 2.09), atrial fibrillation (OR 2.29), hyperkalaemia (K+>5.5 mmol/L; OR 2.63)”
Humansacute decompensated heart failure; K+ >5.5 mmol/Lin-hospitaln = 1,588
Four-pillar era mortality prediction in acute decompensated heart failure: the ICARUS score
ESC Congress 2026 abstract
Zilebesiran
upin humans1RR 3.24
1 study
Zilebesiran
upin humans1RR 3.24
Zilebesiran raises the risk of hyperkalemia in humans (RR 3.24; 95% CI 1.40 to 7.49; p < 0.01).
“zilebesiran was associated with a significantly higher risk of hyperkalaemia (RR 3.24; 95% CI 1.40 to 7.49; p < 0.01)”
Review
ESC Congress 2026 abstract
Nonsteroidal mineralocorticoid receptor antagonists
upin humans1
1 study
Nonsteroidal mineralocorticoid receptor antagonists
upin humans1
Nonsteroidal mineralocorticoid receptor antagonists raise the risk of hyperkalemia in humans (versus placebo).
“Safety analyses showed higher risks of hyperkalemia with nsMRAs and genital infections with SGLT2is than with placebo.”
Human trialversus placebo
Frontiers in endocrinology
Salt substitute
upin humans1
1 study
Salt substitute
upin humans1
Salt substitute raises the risk of hyperkalemia in humans.
“salt substitute increased mean serum potassium and led to more frequent biochemical hyperkalemia”
Human trial2 years
Nature medicine
All 18Fewer
Trial sponsors
Company15 trialsPhase 45,640 people
Company6 trialsPhase 41,102 people
Company3 trialsPhase 31,254 people
Company3 trialsPhase 31,132 people
Company2 trialsPhase 3269 people
1 trialPhase 4419 people
1 trialPhase 4100 people
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
1 trialPhase 460 people
Funding
1 grant since 2026Japan Society for the Promotion of Science¥3.5M
How this record changed
Summary written from the findings.